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Abstract: Background Optimum management of low-grade gliomas remains controversial, and widespread
practice variation exists. This evidence-based meta-analysis evaluates the association of extent of resec-
tion, radiation, and chemotherapy with mortality and progression-free survival at 2, 5, and 10 years in
patients with low-grade glioma. Methods A quantitative systematic review was performed. Inclusion
criteria included controlled trials of newly diagnosed low-grade (World Health Organization Grades I and
II) gliomas in adults. Eligible studies were identified, assigned a level of evidence for every endpoint con-
sidered, and analyzed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses
guidelines. The relative risk of mortality and of progression at 2, 5, and 10 years was calculated for pa-
tients undergoing resection (gross total, subtotal, or biopsy), radiation, or chemotherapy. Results Gross
total resection was significantly associated with decreased mortality and likelihood of progression at all
time points compared to subtotal resection. Early radiation was not associated with decreased mortality;
however, progression-free survival was better at 5 years compared to patients receiving delayed or no
radiation. Chemotherapy was associated with decreased mortality at 5 and 10 years in the high-quality
literature. Progression-free survival was better at 5 and 10 years compared to patients who did not
receive chemotherapy. In patients with isocitrate dehydrogenase 1 gene () R132H mutations receiving
chemotherapy, progression-free survival was better at 2 and 5 years than in patients with wild-type
gliomas. Conclusions Results from this review, the first to quantify differences in outcome associated
with surgery, radiation, and chemotherapy in patients with low-grade gliomas, can be used to inform
evidence-based management and future clinical trials.
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